Clinical Trial Update: Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of temsirolimus plus pemetrexed in recurrent or refractory Non-Small Cell Lung Cancer was terminated, with results posted December 13, 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Torisel (Temsirolimus)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-12-13